Dance Asia Pharma

The “Inhaled Insulin Products” developed by Dance Biopharm revolutionizes the treatment of diabetes, eliminating the pain and inconvenience associated with conventional injection.

HMI possesses the IP and marketing rights of Dance’s products for most countries in Asia. While DongBao Pharmaceuticals is the strategic partner for China, HMI will begin developing markets in India in early 2016. The combined number of patients suffering with diabetes in these two most populous countries is estimated to be in excess of 200 million. China and India will also be the base through which Dance’s products can be exported too other Asian countries.